ClinicalTrials.gg
Active, not recruitingNCT07262268Updated Oct 29, 2026

A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia

A Phase 1 interventional study of BHV-7000 and Placebo in Familial Erythromelalgia, sponsored by Biohaven Therapeutics Ltd.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Biohaven Therapeutics Ltd. · Phase 1, Interventional, and Treatment

Updated Oct 29, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.

Planned enrollment
230th of 261
5 · median 40
Started
2026
with 15 others
Phase 1
20 of 291
6 open now
Primary completion
2027-11
later than 39 of 60 live
Registered
276th of 291
by date

Among the 291 studies in Neuralgia with a site in United States, this one is the 230th largest by planned enrollment of the 261 interventional ones that give a count, is one of 16 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 39 of the 60 other live ones, and was the 276th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Neuralgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.

03

Conditions studied

  • Familial Erythromelalgia

Browse trials for

Keywords

  • Erythomelalgia
  • IEM
  • Primary Erythomelalgia
  • SCN9A
  • NaV1.7
  • Channelopathy
  • Red Neuralgia
  • Neuropathic Pain
  • Inherited Erythomelalgia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Adult men and women between 18 to 75 years of age, inclusive, at time of consent with a diagnosis of inherited erythromelalgia with a previously characterized gain of function NaV1.7 mutation resulting in chronic pain.
  2. Absence of concomitant mutation resulting in Kv7.2/7.3 gain of function.
  3. Ability and willingness to adhere to the study procedures and complete accurate pain diaries
  4. Stable background analgesic regimen for at least 30 days before screening and willingness to maintain the same analgesic regimen during the study period.

Key Exclusion Criteria:

  1. Any laboratory abnormalities or clinically significant abnormalities on screening physical examination, vital signs, or that, in the judgment of the principal investigator, indicates a medical problem that would preclude study participation.
  2. Any medical condition, based on the judgement of the Investigator, that would confound the ability to adequately assess safety and efficacy outcome measures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    BHV-7000

    Drug: BHV-7000

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants will take blinded investigational product (IP) orally once daily

    Also known as: opakalim

  • DrugPlacebo

    Matching placebo taken orally once daily

06

What researchers measure

Primary outcomes

  1. Mean of the daily average maximum pain intensity scores collected every 2 hours.

    Participants will be asked to record peak (worst) pain experienced in the previous 2 hours using an 11-point Likert scale (0-10) where 0=no pain and 10=worst possible pain

    Time frame: The last 3 weeks of each 4-week crossover treatment period

Secondary outcomes

  1. The average weekly frequency of pain attacks on treatment vs. placebo

    Participants will be asked to record occurrence of pain attacks

    Time frame: The last 3 weeks of each 4-week crossover treatment period

  2. The average duration of pain attacks on treatment vs. placebo

    Participants will be asked to record the duration of their pain attacks

    Time frame: The last 3 weeks of each 4-week crossover treatment period

  3. The average peak severity of pain attacks on treatment vs. placebo

    Participants will be asked to record the maximum severity of their pain attacks using an 11-point Likert scale (0-10) where 0=no pain and 10=worst possible pain.

    Time frame: The last 3 weeks of each 4-week crossover treatment period

  4. Safety and tolerability by reporting the frequency of unique participants with SAEs, severe AEs, AEs leading to discontinuation, deaths, and Grade 3-4 (CTCAE/DAIDS) laboratory abnormalities.

    Measured by assessing the number of unique participants who experience treatment-emergent serious adverse events, adverse events leading to discontinuation, or moderate and severe adverse events.

    Time frame: Up to 16 weeks

07

Study locations

1 site
  • Site-001
    New Haven, Connecticut 06520, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.

Of 36 phase 1 interventional studies under Neuralgia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 22 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Nov 2026 → Nov 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 3, 2025
StartActual
Jan 15, 2026
Primary completionEst.
Nov 2027was Nov 2026
CompletionEst.
Nov 2027was Nov 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 29, 2026
Primary completion
Nov 2026→Nov 2027
Oct 29, 2026
Study completion
Nov 2026→Nov 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Nov 2026→Nov 2027
    Study completion Nov 2026→Nov 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07262268
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Jan 15, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 29, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Opakalim

Start the discussion